Brainstorm Cell Therapeutics Inc. has announced that it has entered into a securities purchase agreement with Vanquish Funding Group Inc., under which Vanquish provided funding of $155,000 to the company in exchange for a promissory note with a principal amount of $182,400. The note, which bears interest at 12% and matures on August 30, 2026, is convertible into shares of Brainstorm's common stock at a 35% discount to the lowest trading price in the 10 days prior to conversion, subject to a 4.99% beneficial ownership cap, in the event of a default. The transaction was conducted as a private placement and the conversion shares, when issued, will be exempt from registration under Section 4(a)(2) of the Securities Act. The agreement also provides for the potential of up to $2 million in additional financing from Vanquish over the next twelve months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainstorm Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-107833), on November 06, 2025, and is solely responsible for the information contained therein.
Comments